Chronus Health

Chronus Health, established in 2017 by co-founders Anand Parikh and Ashish Jagtiani, is a medical technology company focused on the point-of-care diagnostics market. The inspiration for the company came from Jagtiani's personal experience with his sister's leukemia diagnosis, where he observed the frustratingly long wait times for blood test results. This led him, a PhD with a background in semiconductor devices and lab-on-a-chip technology from his time at IBM's Thomas J. Watson Research Center, to envision a faster solution. He partnered with his long-time friend, Anand Parikh, a bioengineering graduate with extensive experience in medical devices, to launch the company.

The company is developing a portable, real-time blood testing system designed to deliver lab-quality results within minutes, directly at the point of care. Chronus Health's platform operates similarly to a glucose meter, utilizing a disposable test cartridge with embedded sensors. This system sidesteps the complex and costly optical measurements of traditional, bulky blood analyzers by employing a proprietary electrical sensing approach that combines microfluidics, semiconductors, and machine learning. This enables the device to perform a wide range of tests, including complete blood counts (CBC), complete metabolic panels (CMP), chemistry assays, and immunoassays, on-site. By providing immediately actionable data, the technology aims to significantly reduce diagnosis time, improve patient outcomes, and lower overall healthcare costs.

Chronus Health targets its services toward healthcare settings where rapid blood analysis is critical but often unavailable, such as urgent care centers, skilled nursing facilities, infusion centers, retail clinics, and primary care practices. The business model centers on providing a low-cost, compact system that can handle the majority of common blood tests, challenging the market's reliance on centralized labs for analysis. The company has secured significant financial backing, raising a total of $23.6 million over four funding rounds. Its most recent major funding was a $22 million Series A round in January 2022, led by Tarsadia Investments with participation from Monta Vista Capital, SOSV, and Savantus Ventures.

Keywords: point-of-care diagnostics, blood testing platform, microfluidics, electrical sensing, real-time diagnostics, medtech, in-vitro diagnostics, lab-on-a-chip, portable medical devices, CBC test, CMP test, immunoassay, Anand Parikh, Ashish Jagtiani, Tarsadia Investments, urgent care diagnostics, remote diagnostics, diagnostic equipment, healthcare technology, blood analyzer, point-of-care testing, medical diagnostics, real-time blood analysis, health-tech, rapid diagnostics, clinical decision support